RE:RE:NewsMaybe the big hangup with big pharma at this time is the questions around mechanism for delivery? The tech sounds great, but how will it be administered in order to be as effective as it is in pre-clinical testing? Meaning, is there a way to "get to the cancer" in humans with Rutherrin in as effective a manner as they can do with the cancer in pre-clinical studies? Are they treating cancer cells in petri dishes (or mice) but no way to access the cancer in such an effective manner in humans? Layman's dumb/blind comments, I know. Another angle is, are there lots of companies with these kind of pre-clinical amazmements, but when it comes to human treatments it either doesn't translate or there's just no way to deliver it? It's just something I wonder about as far as why big pharma hasn't perked up yet.